» Articles » PMID: 37786510

Cancer Survivorship at Heart: a Multidisciplinary Cardio-oncology Roadmap for Healthcare Professionals

Abstract

In cancer, a patient is considered a survivor from the time of initial diagnosis until the end of life. With improvements in early diagnosis and treatment, the number of cancer survivors (CS) has grown considerably and includes: (1) Patients cured and free from cancer who may be at risk of late-onset cancer therapy-related cardiovascular toxicity (CTR-CVT); (2) Patients with long-term control of not-curable cancers in whom CTR-CVT may need to be addressed. This paper highlights the importance of the cancer care continuum, of a patient-centered approach and of a prevention-oriented policy. The ultimate goal is a personalized care of CS, achievable only through a multidisciplinary-guided survivorship care plan, one that replaces the fragmented management of current healthcare systems. Collaboration between oncologists and cardiologists is the pillar of a framework in which primary care providers and other specialists must be engaged and in which familial, social and environmental factors are also taken into account.

Citing Articles

Cardiac Metastasis: Epidemiology, Pathophysiology, and Clinical Management.

Luca F, Parrini I, Canale M, Rao C, Nucara M, Pelaggi G Life (Basel). 2025; 15(2).

PMID: 40003702 PMC: 11857090. DOI: 10.3390/life15020291.


Navigating the crossroads: cardiometabolic risks in cancer survivorship - a comprehensive review.

Albulushi A, Al Balushi A, Shahzad M, Al Bulushi I, Al Lawati H Cardiooncology. 2024; 10(1):51.

PMID: 39138547 PMC: 11321223. DOI: 10.1186/s40959-024-00254-w.


Exploring the Perioperative Use of DOACs, off the Beaten Track.

Luca F, Oliva F, Giubilato S, Abrignani M, Rao C, Cornara S J Clin Med. 2024; 13(11).

PMID: 38892787 PMC: 11172442. DOI: 10.3390/jcm13113076.


Navigating the crossroads: cardiometabolic risks in cancer survivorship - a comprehensive review.

Albulushi A, Al Balushi A, Shahzad M, Al Bulushi I, Al Lawati H Cardiooncology. 2024; 10(1):36.

PMID: 38879583 PMC: 11179285. DOI: 10.1186/s40959-024-00240-2.


Cardio-oncology rehabilitation: are we ready?.

Bisceglia I, Venturini E, Canale M, Ambrosetti M, Riccio C, Giallauria F Eur Heart J Suppl. 2024; 26(Suppl 2):ii252-ii263.

PMID: 38784673 PMC: 11110456. DOI: 10.1093/eurheartjsupp/suae030.


References
1.
van Rosendael A, Daniels L, Dimitriu-Leen A, Smit J, van Rosendael P, Schalij M . Different manifestation of irradiation induced coronary artery disease detected with coronary computed tomography compared with matched non-irradiated controls. Radiother Oncol. 2017; 125(1):55-61. DOI: 10.1016/j.radonc.2017.09.008. View

2.
de Baat E, Feijen E, van Niekerk J, Mavinkurve-Groothuis A, Kapusta L, Loonen J . Electrocardiographic abnormalities in childhood cancer survivors treated with cardiotoxic therapy: a systematic review. Pediatr Blood Cancer. 2022; 69(8):e29720. DOI: 10.1002/pbc.29720. View

3.
Saunderson C, Plein S, Manisty C . Role of cardiovascular magnetic resonance imaging in cardio-oncology. Eur Heart J Cardiovasc Imaging. 2021; 22(4):383-396. DOI: 10.1093/ehjci/jeaa345. View

4.
Di Fusco S, Cianfrocca C, Bisceglia I, Spinelli A, Alonzo A, Mocini E . Potential pathophysiologic mechanisms underlying the inherent risk of cancer in patients with atherosclerotic cardiovascular disease. Int J Cardiol. 2022; 363:190-195. DOI: 10.1016/j.ijcard.2022.06.048. View

5.
van Rijswijk J, Farag E, Bouten C, de Boer O, van der Wal A, de Mol B . Fibrotic aortic valve disease after radiotherapy: an immunohistochemical study in breast cancer and lymphoma patients. Cardiovasc Pathol. 2019; 45:107176. DOI: 10.1016/j.carpath.2019.107176. View